Polymorphic variants of SLC26A3 have also been linked to prognosis of patients with colon carcinoma (Dalerba et al., 2011) and to neoadjuvant therapy resistance in HER2-negative breast carcinoma (De Ronde et al., 2013). Here, SLC26A3 is linked to colon carcinoma.